Hubei Jumpcan Pharmaceutical Co Ltd
Hubei Jumpcan Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of drugs in China. The company offers Chinese traditional and Western medicines, daily use chemicals, and medicine health products in various formulations. Its products are used in the areas of detoxification, digestive system, pediatric, respiratory system, nervous system, anti-infection, cardiovasc… Read more
Hubei Jumpcan Pharmaceutical Co Ltd (600566) - Total Assets
Latest total assets as of September 2025: CN¥16.53 Billion CNY
Based on the latest financial reports, Hubei Jumpcan Pharmaceutical Co Ltd (600566) holds total assets worth CN¥16.53 Billion CNY as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Hubei Jumpcan Pharmaceutical Co Ltd - Total Assets Trend (1998–2024)
This chart illustrates how Hubei Jumpcan Pharmaceutical Co Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Hubei Jumpcan Pharmaceutical Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Hubei Jumpcan Pharmaceutical Co Ltd's total assets of CN¥16.53 Billion consist of 79.6% current assets and 20.4% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 36.1% |
| Accounts Receivable | CN¥2.27 Billion | 12.3% |
| Inventory | CN¥569.09 Million | 3.1% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥310.74 Million | 1.7% |
| Goodwill | CN¥167.30 Million | 0.9% |
Asset Composition Trend (1998–2024)
This chart illustrates how Hubei Jumpcan Pharmaceutical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Hubei Jumpcan Pharmaceutical Co Ltd's current assets represent 79.6% of total assets in 2024, an increase from 36.6% in 1998.
- Cash Position: Cash and equivalents constituted 36.1% of total assets in 2024, up from 5.5% in 1998.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, a decrease from 16.0% in 1998.
- Asset Diversification: The largest asset category is accounts receivable at 12.3% of total assets.
Hubei Jumpcan Pharmaceutical Co Ltd Competitors by Total Assets
Key competitors of Hubei Jumpcan Pharmaceutical Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Hubei Jumpcan Pharmaceutical Co Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Hubei Jumpcan Pharmaceutical Co Ltd generates 0.43x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Excellent ROA - For every $100 in assets, Hubei Jumpcan Pharmaceutical Co Ltd generates $ 13.71 in net profit.
Hubei Jumpcan Pharmaceutical Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.32 | 3.72 | 3.34 |
| Quick Ratio | 5.18 | 3.55 | 3.20 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥10.51 Billion | CN¥ 10.50 Billion | CN¥ 4.61 Billion |
Hubei Jumpcan Pharmaceutical Co Ltd - Advanced Valuation Insights
This section examines the relationship between Hubei Jumpcan Pharmaceutical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.81 |
| Latest Market Cap to Assets Ratio | 0.07 |
| Asset Growth Rate (YoY) | 1.7% |
| Total Assets | CN¥18.46 Billion |
| Market Capitalization | $1.21 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Hubei Jumpcan Pharmaceutical Co Ltd's assets below their book value (0.07 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Hubei Jumpcan Pharmaceutical Co Ltd's assets grew by 1.7% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Hubei Jumpcan Pharmaceutical Co Ltd (1998–2024)
The table below shows the annual total assets of Hubei Jumpcan Pharmaceutical Co Ltd from 1998 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥18.46 Billion | +1.74% |
| 2023-12-31 | CN¥18.14 Billion | +21.11% |
| 2022-12-31 | CN¥14.98 Billion | +23.49% |
| 2021-12-31 | CN¥12.13 Billion | +15.36% |
| 2020-12-31 | CN¥10.52 Billion | +21.36% |
| 2019-12-31 | CN¥8.66 Billion | +11.12% |
| 2018-12-31 | CN¥7.80 Billion | +17.03% |
| 2017-12-31 | CN¥6.66 Billion | +33.58% |
| 2016-12-31 | CN¥4.99 Billion | +39.11% |
| 2015-12-31 | CN¥3.59 Billion | +6.78% |
| 2014-12-31 | CN¥3.36 Billion | +66.68% |
| 2013-12-31 | CN¥2.01 Billion | +102.89% |
| 2012-12-31 | CN¥992.87 Million | +3.23% |
| 2011-12-31 | CN¥961.82 Million | +11.43% |
| 2010-12-31 | CN¥863.16 Million | +3.22% |
| 2009-12-31 | CN¥836.22 Million | +0.80% |
| 2008-12-31 | CN¥829.61 Million | +3.40% |
| 2007-12-31 | CN¥802.32 Million | +2.01% |
| 2006-12-31 | CN¥786.51 Million | +7.42% |
| 2005-12-31 | CN¥732.21 Million | +4.92% |
| 2004-12-31 | CN¥697.90 Million | +7.31% |
| 2003-12-31 | CN¥650.39 Million | +7.11% |
| 2002-12-31 | CN¥607.22 Million | +4.22% |
| 2001-12-31 | CN¥582.65 Million | +160.83% |
| 2000-12-31 | CN¥223.38 Million | +13.57% |
| 1999-12-31 | CN¥196.69 Million | +5.61% |
| 1998-12-31 | CN¥186.23 Million | -- |